Using PET/CT imaging to assess prostate cancer
Diagnostic Performance of 18F-prostate-specific Membrane Antigen-1007 PET/CT in the Detection of Prostate Cancer
This study is testing a new type of imaging to see if it can better help men with prostate cancer understand their disease and avoid unnecessary treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 40 Years to 100 Years |
| Sex | Male |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT04521894 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 18F-prostate-specific membrane antigen PET/CT imaging in accurately staging prostate cancer and determining the risk of metastasis. It aims to improve the management of prostate cancer by providing a more objective assessment compared to traditional methods like PSA testing and biopsies. The study includes men aged 40 to 100 with specific PSA levels and confirmed prostate cancer diagnoses, while excluding those without histological confirmation or who have undergone certain therapies. By focusing on precise risk stratification, the study seeks to reduce unnecessary invasive procedures and improve treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates are men aged 40 to 100 with biopsy-proven prostate cancer and specific PSA levels indicating potential metastasis.
Not a fit: Patients without a confirmed histological diagnosis of prostate cancer or those who have recently undergone pharmacotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate risk assessments and personalized treatment plans for prostate cancer patients.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques for prostate cancer assessment, suggesting this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1 age between 40 and 100 years old * 2 PSA \>0.4 ng/mL for primary PCa with biopsy proven or RP diagnosis of prostate cancer * 3 PSA \>0.2 ng/mL after RP, PSA ≥2 ng/mL above the nadir after EBRT) or persisting PSA after radical treatment with rising PSA values * 4 complete clinical, pathological, imaging and biochemical information Exclusion Criteria: * 1 lack of histological examinationproven diagnosis of PCa * 2 18F-PSMA PET/CT being performed after pharmacotherapy since PSMA-targeted imaging can be disturbed by previous therapie
Where this trial is running
Xi'an, Shaanxi
- First Affiliate Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Study coordinator: Xiaoyi Duan, Ph.D.
- Email: duanxy@xjtu.edu.cn
- Phone: 0086-029-85324741
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.